Related Experiment Video
Updated: Sep 15, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
New Drugs for Resistant Hypertension: Pending Issue?
Francesco Fici1, Nicolas Roberto Robles2, Istemihan Tengiz3
1Department of Cardiovascular Risk, Salamanca University, Salamanca, Spain;Milano-Bicocca University, Milan, Italy.
Abstract:
Antihypertensive pharmacological treatment, based on currently available drugs, has been shown to reduce the cardiovascular risk profile of the treated hypertensive patients by lowering elevated blood pressure values. However, the risk of the treated hypertensive patients remains elevated. This represents the rationale for developing new antihypertensive drugs capable to normalize cardiovascular risk related to uncontrolled high blood pressure. This paper is designed at reviewing new antihypertensive drugs for the treatment of drug-resistant hypertension. The review will focus in particular on the results obtained with non-steroidal mineralcorticoid receptors antagonists, aldosterone synthase inhibitors, brain renin-angiotensin blockers, hepatic angiotensinogen inhibitors, atrial natriuretic peptides and endothelin 1 receptors antagonists.
More Related Videos
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Direct Renin Inhibitors
Hypertension IV: Drug Therapy and Lifestyle Modifications
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Heart Failure Drugs: Diuretics
Heart Failure V: Medical Management

